Therapeutic effects of a recombinant mutant of the human ciliary neurotrophic factor in a mouse model of metabolic syndrome.
Metabolic syndrome (MS) is highly prevalent in developed countries and becoming a serious worldwide public health issue. In this study, we established a MS model by feeding male C57BL/6J mice with a high-fat diet (10%) for 18.5 weeks, studied the therapeutic effects of a recombinant mutant of the human ciliary neurotrophic factor (rhmCNTF) 0.1 (C-0.1) or 0.3 (C-0.3) mg x kg(-1) per day subcutaneously or pair feeding (PF, which mice were restricted to the same amount of food as eaten by C-0.3 treated mice) in MS mice. After 10 days treatment, rhmCNTF reduced obesity related indices, ameliorated glucose and lipid metabolism abnormality, and enhanced insulin sensitivity. In addition, liver function and antioxidant ability of MS mice were improved by rhmCNTF. Pair feeding revealed the same effects as C-0.3 on obesity related indices and insulin sensitivity, but aggravated hepatic steatosis and hepatic function. The results suggest that rhmCNTF could serve as an effective therapeutic agent for MS and related diseases.
Cui
Ming-Xia
MX
Institute of Pharmacology, School of Basic Medical Science, Lanzhou University, Gansu Province Key Laboratory of Preclinical Study for New Drugs, Lanzhou, China.
Jiang
Jun-Feng
JF
Zheng
Rong-Liang
RL
Li
Rui-Lian
RL
Wang
Lei
L
Li
Wen-Guang
WG
Gao
Ming-Tang
MT
Yang
Li-Ning
LN
Dou
Jin-Yan
JY
Wu
Yong-Jie
YJ
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D020934:Ciliary Neurotrophic Factor / Q000097:blood / Q000627:therapeutic use*; D004032:Diet; D004041:Dietary Fats; D005234:Fatty Liver / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D024821:Metabolic Syndrome / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009765:Obesity / Q000188:drug therapy / Q000209:etiology; D011994:Recombinant Proteins / Q000627:therapeutic use
D000975:Antioxidants; D001786:Blood Glucose; D020934:Ciliary Neurotrophic Factor; D004041:Dietary Fats; D008055:Lipids; D011994:Recombinant Proteins; D008315:Malondialdehyde